Capricor Therapeutics
8840 Wilshire Blvd
2nd Floor
Beverly Hills
California
90211
United States
211 articles about Capricor Therapeutics
-
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
6/17/2022
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year’s Parent Project Muscular Dystrophy Conference.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
5/25/2022
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has appointed Xavier Avat as Chief Business Officer.
-
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/18/2022
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida.
-
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
5/3/2022
Capricor Therapeutics will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022.
-
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
3/29/2022
Capricor Therapeutics announced that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022.
-
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
3/28/2022
Capricor Therapeutics announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19.
-
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
3/11/2022
Capricor Therapeutics (NASDAQ: CAPR), announced today that The Lancet, a renowned peer-reviewed global medical source for clinical and global health, has published positive results from Capricor’s HOPE-2 Phase 2 clinical trial using lead asset, CAP-1002, to treat patients in advanced stages of Duchenne muscular dystrophy (DMD).
-
Capricor Therapeutics announced less-than-stellar Q4 2021 and full-year 2021 financial results and said the company stopped efforts on its COVID-19 vaccine.
-
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/10/2022
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today its financial results for the fourth quarter and full year 2021 and provided a corporate update.
-
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET
3/3/2022
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the fourth quarter and full year ended December 31, 2021, after the market close on Thursday, March 10, 2022.
-
Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
3/2/2022
Capricor Therapeutics announced the expansion of its Senior Leadership team with the appointment of Daniel Paulson, M.D. as Vice President of Clinical Development.
-
Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US
1/25/2022
Nippon Shinyaku Co., Ltd. announced today that Nippon Shinyaku and Capricor Therapeutics (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ: CAPR) have entered into an exclusive distribution agreement for CAP-1002 for the treatment* of Duchenne muscular dystrophy (DMD) in the territory of US.
-
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
1/25/2022
Capricor Therapeutics announced that it has entered into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company listed on the TYO, for the exclusive commercialization and distribution in the United States of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy, a rare neuromuscular disease with limited treatment options.
-
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
12/13/2021
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced new updates on its vaccine and therapeutic development programs focused on COVID-19.
-
Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
11/12/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that Dr. Linda Marbán, CEO of Capricor, has accepted an invitation to serve as the keynote speaker at the TriLink Biotechnologies Annual mRNA Day Conference, taking place virtually on November 16, 2021.
-
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/9/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, reported its financial results for the third quarter ended September 30, 2021, and provided an overview of its recent operational highlights.
-
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET
11/2/2021
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.